Analyst Price Targets — RLMD
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| June 18, 2026 10:01 am | — | H.C. Wainwright | $12.00 | $6.60 | TheFly | Relmada Therapeutics initiated with a Buy at H.C. Wainwright |
| March 13, 2026 6:49 pm | Uy Ear | Mizuho Securities | $10.00 | $5.91 | StreetInsider | Mizuho Reiterates Outperform Rating on Relmada Therapeutics Inc (RLMD): pullback 'a buying opprotunity' |
| January 23, 2026 11:24 am | — | Leerink Partners | $8.00 | $3.96 | TheFly | Relmada Therapeutics assumed at Outperform from Market Perform at Leerink |
| December 22, 2025 12:08 am | — | Jefferies | $9.00 | $4.35 | TheFly | Relmada Therapeutics initiated with a Buy at Jefferies |
| June 5, 2024 3:55 am | Andrea Tan | Goldman Sachs | $2.00 | $2.95 | StreetInsider | Goldman Sachs Downgrades Relmada Therapeutics Inc (RLMD) to Sell |
| October 13, 2022 3:47 pm | Andrew Tsai | Jefferies | $8.00 | $6.48 | TheFly | Relmada Therapeutics downgraded to Hold from Buy at Jefferies |
| October 13, 2022 11:55 am | Jay Olson | Oppenheimer | $7.00 | $6.75 | TheFly | Relmada downgraded to Perform at Oppenheimer after MDD monotherapy trial miss |
Latest News for RLMD
CORAL GABLES, Fla., July 16, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced plans to host a conference call and webcast on Thursday, August 6, 2026 at 4:30 PM ET to discuss financial results for the second quarter ended June 30,…
CORAL GABLES, Fla., June 29, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced that the Company joined the Russell 2000® Index and the Russell 3000® Index effective after the U.S. market closed on June 26, 2026, as part of the Russell…
On Thursday, HC Wainwright initiated coverage on Relmada Therapeutics Inc. (NASDAQ:RLMD) with a primary focus on bladder cancer treatment regimen.
CORAL GABLES, Fla., June 11, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced the appointment of Michael Quirk, PhD, as Senior Advisor – Sepranolone Program. Dr. Quirk's deep expertise in CNS translational science, neuroactive steroid…
CORAL GABLES, Fla., May 28, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced that Sergio Traversa, Chief Executive Officer, and Maged Shenouda, Chief Financial Officer, will participate in the Jefferies Global Healthcare Conference…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for RLMD.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.